Daily Archives: May 9, 2021

This report studies the Fingerprint Biometrics in the VAR market in many aspects of the industry such as market size, market conditions, market trends and forecasts, and the report also provides brief information on competitors and specific growth opportunities with key market drivers. To provide, find complete Fingerprint Biometrics in the VAR market analysis segmented by company, region, type and application in the report.

The report provides regional analysis and valuable insights into the progress of the Fingerprint Biometrics in the VAR market and approaches related to the Fingerprint Biometrics in the VAR market. The report talks about the dominant aspects of the market and examines each segment.

Top Companies in the Fingerprint Biometrics in the VAR Market- Fulcrum Biometrics, Delaney Secure Ltd., Neurotechnology, 360 Biometrics, AKSA Solution Development, AutoStar Technologies, Bayometric, Bromba Biometrics, California Peripherals and Components, Digital Data Systems, DYDEX-HS, Eyenetwatch and other.

(Exclusive Offer: Flat 25% discount on this report)

Get a Free sample copy of the Fingerprint Biometrics in the VAR market report

https://www.marketinsightsreports.com/reports/10302408993/global-and-china-fingerprint-biometrics-in-the-var-market-size-status-and-forecast-2020-2026/inquiry?mode=126

1.Company Profile

Segment by Type

Non-AFIS Biometrics in VAR

AFIS Biometrics in VAR

Segment by Application

Commercial

Household

Others

Read Full Fingerprint Biometrics in the VAR Market Report (Description, TOC, List of Tables & Figures, and Many More) at:

https://www.marketinsightsreports.com/reports/10302408993/global-and-china-fingerprint-biometrics-in-the-var-market-size-status-and-forecast-2020-2026?mode=126

Geographic Coverage-The report contains detailed country-level analysis, market revenue, market value and forecast analysis of ingestion, revenue and Fingerprint Biometrics in the VAR Market share, growth speed, historical and forecast (2015-2026) of these regions are covered:

-North America (the United States, Canada, and Mexico)

-Europe (Germany, France, UK, Russia, and Italy)

-Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

-South America (Brazil, Argentina, etc.)

-Middle East & Africa (Saudi Arabia, Egypt, Nigeria, and South Africa)

The current market situations and prospects of the sector also have been examined. Additionally, prime strategical activities in the market, which include product developments, mergers, and acquisitions, partnerships, etc., are discussed. Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products, etc.)

Major Points Covered in Table of Contents:

Overview of Fingerprint Biometrics in the VAR Market Global Market Status and Forecast by Regions Global Market Status and Forecast by Types Global Market Status and Forecast by Downstream Industry Market Driving Factor Analysis Market Competition Status by Major Manufacturers Major Manufacturers Introduction and Market Data Upstream and Downstream Market Analysis Cost and Gross Margin Analysis Marketing Status Analysis Market Report Conclusion Research Methodology and Reference

Key Questions Answered by Fingerprint Biometrics in the VAR Market Report

We additionally offer customization on reports based on customer necessity:

1- Free Country-level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any 5 key market players.

3- Free 40 analyst hours to cover any other data points.

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information, and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

sales@marketinsightsreports.com| irfan@marketinsightsreports.com

View original post here:

Fingerprint Biometrics in the VAR Market In-depth Profiling of Key Players and Recent Developments and Forecast Period to 2026|Fulcrum Biometrics,...

News Release

Monday, May 3, 2021

NIH BRAIN Initiative-funded study opens the door to correlating deep brain activity and behavior.

Researchers are now able to wirelessly record the directly measured brain activity of patients living with Parkinsons disease and to then use that information to adjust the stimulation delivered by an implanted device. Direct recording of deep and surface brain activity offers a unique look into the underlying causes of many brain disorders; however, technological challenges up to this point have limited direct human brain recordings to relatively short periods of time in controlled clinical settings.

This project, published in the journal Nature Biotechnology, was funded by the National Institutes of Healths Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative.

This is really the first example of wirelessly recording deep and surface human brain activity for an extended period of time in the participants home environment, said Kari Ashmont, Ph.D., project manager for the NIH BRAIN Initiative. It is also the first demonstration of adaptive deep brain stimulation at home.

Deep brain stimulation (DBS) devices are approved by the U. S. Food and Drug Administration for the management of Parkinsons disease symptoms by implanting a thin wire, or electrode, that sends electrical signals into the brain. In 2018, the laboratory of Philip Starr, M.D., Ph.D. at the University of California, San Francisco, developed an adaptive version of DBS that adapts its stimulation only when needed based on recorded brain activity. In this study, Dr. Starr and his colleagues made several additional improvements to the implanted technology.

This is the first device that allows for continuous and direct wireless recording of the entire brain signal over many hours, said Dr. Starr. That means we are able to perform whole brain recording over a long period of time while people are going about their daily lives.

The implications of this type of recording are significant. The brain activity patterns (neural signatures) normally used to identify problems such as Parkinsons disease symptoms have traditionally been recorded in clinical settings over short periods of time. This new technology makes it possible to validate those signatures during ordinary daily activities.

If you ever hope to use in-hospital recordings to modify a disease state through adaptive stimulation, you must show that they are also valid in the real world, said Dr. Starr.

Another advantage to recording over long periods of time is that distinct changes in brain activity (biomarkers) that could predict movement disorders can now be identified for individual patients. Roee Gilron, Ph.D., a postdoctoral scholar in Dr. Starrs lab and first author of this study, explained that this allows for a level of customized DBS treatment that was impossible to achieve previously.

Because we are able to build a biomarker library for each patient, we can now program each DBS unit according to a patients individual needs, said Dr. Gilron. This includes personalized stimulation programs that adapt as the patients needs change throughout the day.

One important consideration that arises is the ethical implication of (nearly) all-day brain recording. Since its beginning, the NIH BRAIN Initiative has recognized the importance of addressing potential ethical considerations pertaining to the development and use of devices that record or modulate brain activity. For instance, the NIH BRAIN Neuroethics Working Group is a group of experts in neuroethics and neuroscience that serves to provide the NIH BRAIN Initiative with input relating to neuroethicsa field that studies the ethical, legal, and societal implications of neuroscience. Alongside funding for neurotechnology research, the Initiative also funds research on the ethical implications of advancements in neurotechnology.

We have had patients approach us with concerns regarding privacy, said Dr. Starr. Although we are not at the point where we can distinguish specific normal behaviors from brain activity recording, it is an absolutely legitimate concern. We have told patients to feel free to remove their wearable devices and to turn off their brain recordings whenever they engage in activities they would like to keep private.

The patients were also invited to participate in NIH BRAIN Initiative-funded neuroethics projects looking to identify concerns about this new technology (MH114860). In addition, individuals who opted out of the implant project were interviewed about their decision. As recommended by a recent BRAIN 2.0 neuroethics report, this information will be used to develop ethical guidelines and protocols for future projects to achieve a healthy balance between discovery and privacy.

One unforeseen benefit of this study was that, because it required little to no direct contact with clinicians following surgery, it was ideally suited for the social distancing that is crucial during the COVID-19 pandemic. The technologies used for remote patient monitoring and telehealth were originally designed for the convenience of study subjects, but they have broader applications to other research projects that have been stalled due to COVID-19.

The technologies we developed and used to communicate and work remotely with our patients can also allow those who do not live close to a clinic to receive over the air updates for their devices and telehealth visits from their neurologists as they manage increasingly complex DBS devices, said Dr. Gilron.

The importance of studying behavior in a natural environment such as the home as it relates to neural activity was emphasized in a recent BRAIN 2.0 neuroscience report. Dr. Ashmont stressed that this study is a significant step in that direction and is going to help scientists understand not only disorders but also the neural representation of behaviors in general.

This research was funded by a grant from the NIH BRAIN Initiative (NS100544).

The NIH BRAIN Initiativeis managed by 10 institutes whose missions and current research portfolios complement the goals of The BRAIN Initiative: National Center for Complementary and Integrative Health, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Drug Abuse, National Institute on Deafness and other Communication Disorders, National Institute of Mental Health, and National Institute of Neurological Disorders and Stroke.

NINDS(http://www.ninds.nih.gov) is the nations leading funder of research on the brain and nervous system.The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Gilron, R. et al., Chronic wireless streaming of invasive neural recordings at home for circuit discovery and adaptive stimulation.Nature BiotechnologyMay 3, 2021. DOI:10.1038/s41587-021-00897-5

###

Originally posted here:

Researchers wirelessly record human brain activity during normal life activities - National Institutes of Health

Vancouver, British Columbia--(Newsfile Corp. - May 3, 2021) - The global Neurostimulation Devices Market will be worth USD 13.70 Billion by 2027, according to a current analysis by Emergen Research. The growth of this market can be attributed to the growing incidence of health disorders due to unhealthy lifestyle habits is expected to drive the growth of the neurostimulation devices market. Recent developments in neurotechnology are resulting in the rapid utilization of neurostimulation therapies in treating patients suffering from neurological disorders. The economic development and increasing Healthcare Budgetary Allocation in developing countries is expected to drive the growth of the neurostimulation devices market.

The high cost of the neurostimulation devices and the presence of alternative therapeutic procedures is most likely to hamper the demand for neurostimulation devices over the forecast period. Adverse effects and risks associated with neurostimulation devices such as allergic reaction or prickling of skin might restrict the utilization of the neurostimulation devices. Moreover, Stringent government regulations on device approval might act as a barrier to the growth of the market.

Claim Your FREE Sample Copy with Table of content @ https://www.emergenresearch.com/request-sample/349

Key Highlights From The Report

Key companies include Boston Scientific Corporation, St. Jude Medical, Medtronic, Neuronetics, Inc., Codman & Shurtleff, Inc., Nevro Corporation, Intrapace, Abbott Laboratories, LivaNova PLC, and Bayer AG, among others.

In September 2019, U.S. Food and Drug Administration (FDA) approved Abbott's Proclaim XR recharge free neurostimulation platform for people living with chronic pain. The approval helped Abbott to secure a higher market share and increase its neurostimulation devices product portfolio.

Deep Brain Stimulators held the second largest market share of 19.8% in 2019. The rising incidence of neurological disorders among the rising global geriatric population is expected to boost the demand for Deep Brain Stimulators.

Urinary and Fecal Incontinence is expected to register steady growth over the forecast period. Increasing utilization of the sacral nerve stimulators for the treatment of Urinary and Fecal Incontinence is expected to drive the growth of the neurostimulation devices market.

North America accounted for the largest market share of the Neurostimulation Devices market in 2019 due to the improved healthcare system and government funding for the research and development of neurostimulation devices.

Check Our Prices @ https://www.emergenresearch.com/select-license/349

Story continues

Emergen Research has segmented the global Neurostimulation Devices Market on the basis of Product, Application, and region:

Product Outlook (Revenue, USD Billion; 2017-2027)

Application Outlook (Revenue, USD Billion; 2017-2027)

Click to access the Report Study, Read key highlights of the Report and Look at Projected Trends: https://www.emergenresearch.com/industry-report/neurostimulation-devices-market

Take a Look at our Related Reports:

Organs-on-Chips Market By Type (Liver-on-Chip, Multiple Organs-on-Chips, Kidney-on-Chip, Heart-on-Chip, Lung-on-Chip, Intestine-on-Chip), By Application (Drug Discovery, Physiological Model Development, Toxicology Research), By End-Use (Pharmaceutical Firms, Research Institutes, Personal Care Industry), and By Region Forecast to 2028

RNA Transcriptomics Market By Product (Reagents, Instruments, Software, Service), By Technology (Microarrays, Polymerase Chain Reaction, RNA Sequencing, RNA Interference), By Application (Clinical Diagnostics, Toxicogenomics, Drug Discovery, Comparative Transcriptomics), By End-Use (Hospitals, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations), and By Region

Slide Stainers Market By Product (Reagents, Consumables & Accessories, Equipment), By Technology (Hematoxylin and Eosin, Immunohistochemistry, In Situ Hybridization, Cytology, Microbiology, Hematology, Special Stains), By End-Use (Hospitals and Diagnostic Centers, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Other), and By Region Forecast to 2028

High-performance Liquid Chromatography (HPLC) Market By Product (Instruments, Accessories, Consumables), By Application (Clinical Research, Forensic, Diagnostics, Other), By End-Use (Pharma and Bio-pharmaceutical Companies, Contract Research Organizations, Academic Institutions and Others), and By Region Forecast to 2028

Flow Imaging Microscopy Market By Sample Type (Large Biomolecule, Small Biomolecules, Liquid & Viscous Samples, Microfibers and Nano fibers, Others), By Sample Dispersion (Wet Dispersion, Dry Dispersion), By End-Use (Biotechnology Companies, Pharmaceutical Companies, Water Testing Laboratories, Food & Beverage Companies, Research & Academia, Metal Manufacturing, Chemical & Petrochemical Industries), and By Region Forecast to 2028

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric LeeCorporate Sales SpecialistEmergen Research | Web: http://www.emergenresearch.comDirect Line: +1 (604) 757-9756E-mail: sales@emergenresearch.comFacebook | LinkedIn | Twitter | Blogs

Read Full Press Release @ https://www.emergenresearch.com/press-release/global-neurostimulation-devices-market

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/82677

Read the original:

Neurostimulation Devices Market Worth USD 13.70 Billion by 2027: Rising Geriatric Population, Coupled with Increasing Prevalence of Neurological...

Leerink Partners analyst Richard Newitter maintained a Buy rating on Stryker Corporation (NYSE:) on Wednesday, setting a price target of $290, which is approximately 10.42% above the present share price of $262.63.

Newitter expects Stryker Corporation to post earnings per share (EPS) of $0.80 for the second quarter of 2021.

The current consensus among 20 TipRanks analysts is for a Moderate Buy rating of shares in Stryker, with an average price target of $277.The analysts price targets range from a high of $303 to a low of $248.

In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $3.95 billion and a net profit of $465 million. The company's market cap is $98.83 billion.

According to TipRanks.com, Leerink Partners analyst Richard Newitter is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 28.1% and a 70.43% success rate.

Michigan-based Stryker Corp. was founded in 1941. The company provides medical technology products and services. It operates its business through the following segments: Orthopaedics, MedSurg and Neurotechnology and Spine.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Visit link:

Leerink Partners Stick to Their Buy Rating for Stryker Corporation By Investing.com - Investing.com

Groundbreaking cognitive assessment tool helps improve diagnostic process and outcomes

Add after eleventh paragraph of release: To get in touch with HeadworX visit headworxclinic.com.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210503005334/en/

The updated release reads:

HEADWORX CHOOSES VOXNEURO INNOVATION TO ENHANCE PATIENT CARE

Groundbreaking cognitive assessment tool helps improve diagnostic process and outcomes

A leading neurophysiological testing facility has selected VoxNeuros innovative technology to provide its patients with more certainty in the diagnosis and treatment of brain conditions, VoxNeuro announced today.

HeadworX, led by neurologist Dr. Abdel Kaleel, MD, M.Sc in Kitchener-Waterloo, is integrating VoxNeuros groundbreaking Cognitive Health Assessment into its clinical practice.

"Our ability to offer the VoxNeuro Cognitive Health Assessment will be an incredible extension to our clinical exam, allowing us to develop a more realistic and complete picture of the patient's road to recovery," said Dr. Kaleel.

Dr. John F. Connolly, Chief Science Officer and Co-Founder of VoxNeuro, said HeadworX is a much-needed leader in this area.

"Neurology as a profession has been deeply rooted in tradition," he said. "Dr. Kaleel and his colleagues are future-focused and invested in adopting new and innovative technology that can improve his patients medical evaluation and outcomes."

VoxNeuros breakthrough neurotechnology precisely scores cognitive performance by measuring biomarkers in the electrical activity of the brain, much like using a cardiogram to measure the health of the heart. VoxNeuros technology is positioned to globally change the way brain health is managed and treated with their rapid, precise scores of cognitive function including memory, information processing, attention and concentration.

This provides valuable data to the diagnostic process, enabling clinicians to make more accurate diagnoses faster. The data also helps to customize treatments and accurately track how well treatments are working overtime, thus helping to ensure the best possible outcomes for patients.

Story continues

"We welcome the innovation of VoxNeuro because I have long believed that, as a field, we can do a better job of providing patients with the answers they deserve and a clear path to recovery," says Dr. Kaleel. "With the addition of VoxNeuro, our patients can feel very comfortable that we have the most current means of giving them a true understanding of their condition and an ongoing way to ensure their treatment is working."

Backed by more than 30 years of global, peer-reviewed scientific research, VoxNeuros assessment will also help to ease pressure on the healthcare system as a whole.

"With our growing community population, there is a widening gap for neurological services in Canada," says Dr. Kaleel. "Many times, patients are over-treated and over-tested and this can place a substantial burden on our healthcare system and subject the patient to unnecessary harm. With the objective data provided by VoxNeuro, we will be better able to determine if a patients cognitive concerns warrant further investigations or management options."

HeadworX serves patients across southwest Ontario, aged from teens to the elderly. The VoxNeuro assessment will augment the clinics current array of tools which includes Electromyography (EMG), Electro-encephalography (EEG), Transcranial Doppler (TCD) and Ambulatory Blood Pressure Monitor (ABP).

To get in touch with HeadworX visit headworxclinic.com.

About VoxNeuro Give your brain a voice

VoxNeuro is backed by more than 30 years of peer-reviewed scientific research and offers the only neurotechnology that scores multiple cognitive functions to support proactive brain health, informed clinical decision-making and customized care. By analyzing the electrical activity of the brain, VoxNeuro scores its cognitive performance in memory, information processing, attention & concentration.

VoxNeuro is headquartered at McMaster Innovation Park in Hamilton, ON, Canada.

Appointments available at VoxNeuro Test Centers. To learn more, follow VoxNeuro on LinkedIn, Twitter, Instagram, Facebook and YouTube or visit http://www.voxneuro.com.

Ask us about being selected as 1 of 11 emerging growth Canadian Life Sciences Companies by the Government of Canadas Trade Commissioner Service.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005334/en/

Contacts

Media: Connie Burkeinfinitycomm416-809-0766connie@infinitycomm.ca

Excerpt from:

ADDING and REPLACING HeadworX Chooses VoxNeuro Innovation to Enhance Patient Care - Yahoo Finance